Why the study?
Does everyday dark chocolate intake reduce the risk of cardiometabolic disorders in hospitalized patients?
Does everyday dark chocolate intake reduce the risk of cardiometabolic disorders in hospitalized patients?
Daily consumption of dark chocolate (>35% cocoa) was associated with a significant reduction in the risk of cardiovascular disease, mortality, and incident diabetes over a 5-year period.
Answers are grounded in this paper and cite their sources.
Daily dark chocolate intake was associated with lower CVD risk; leaves open causality and requires RCT confirmation before practice change.
Scientific research proves that the cardiac and the metabolic functions are improved by the consumption of flavonoids, natural elements found in cocoa. The dark chocolate is the main alimentary compound rich in flavonoids, and for this reason it can be used to prevent some cardiometabolic disorders. This study aims to demonstrate the relationship between chocolate consumption and the cardiometabolic disorders risk in 85 patients hospitalized in Internal Medicine Unit of Emergency Hospital “St. Apostle Andrew” of Constanta. Patients were split according to the quantity of the dark chocolate consumption into 2 groups. The study groups were matched by the demographic parameters, the BMI, the physical activity and other risk factors (fats, saturated lipids, etc). We found that the daily consumption of dark chocolate, with content of cocoa > 35% according to European recommendations, had cardiometabolic benefits. The risk of coronary heart disease was reduced with 23% by the daily dark chocolate intake. The cardiovascular disease mortality and the risk of any cardiovascular disease were decreased with 19%, respectively with 38%. The risk of incident diabetes decreased with 28% after daily dark chocolate consumption, regardless the gender of patients. The number of ischemic cerebral events was reduced with 32%. In summary, the daily consumption of dark chocolate rich in flavonoids decreases the cardiometabolic disorders in patients at risk [1].
No takes yet. Share an insight, caveat, or question.
Andra-Iulia et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: